The endocrine basis of benign breast disorders

@article{Dogliotti2005TheEB,
  title={The endocrine basis of benign breast disorders},
  author={Luigi Dogliotti and Fabio Orlandi and Alberto Angeli},
  journal={World Journal of Surgery},
  year={2005},
  volume={13},
  pages={674-679}
}
There is sound clinical evidence that many benign breast conditions, especially pain, nodularity, and cysts, are likely to have their pathogenesis in hormonal events during reproductive life. Yet the classical theories of persisting hyperestrogenism and luteal progestogen deficiency have not stood up to detailed investigation. Recent work has demonstrated the importance of dynamic hormonal changes and of chronobiological rhythms—daily, menstrual, and seasonal. Recent developments and findings… 

Evaluation and management of breast pain.

TLDR
Most patients with breast pain respond favorably to a combination of reassurance and nonpharmacological measures, and the medications danazol, tamoxifen, and bromocriptine are effective; however, the potentially serious adverse effects of these medications limit their use to selected patients with severe, sustained breast pain.

The association of fibrocystic breast disease with endometrial histopathological results in abnormal uterine bleeding

TLDR
It is found that women with FBD have an increased risk for endometrial hyperplasia andendometrial polyp, a precursor lesion for endometricrial cancer, and clinicians should pay attention to and investigate menstrual bleeding abnormalities of women withFBD and should not delay the evaluation of the endometrium.

A Randomized Pilot Study of Inositol in Association with Betaine and Boswellia in the Management of Mastalgia and Benign Breast Lump in Premenopausal Women

TLDR
The combination of boswellic acid, betaine, and myoinositol has been demonstrated to be effective in the treatment of breast pain and radiologically and histologically confirmed benign breast mass and in the reduction of breast density, one of the pivotal risk factors for the development of breast cancer, without any side effects.

Is hyperandrogenemia protective for fibrocystic breast disease in PCOS?

  • E. OzkayaE. Cakir T. Kucukozkan
  • Medicine, Biology
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2012
TLDR
Group 3 ovulatory PCOS patients with PCO and hyperandrogenemia phenotype had lower risk to develop fibrocystic disease, while higher rates were observed in group 1 anovulatory-normoandrogenemic PCos patients.

Polycystic ovary syndrome and fibrocystic breast disease: is there any association?

TLDR
This study showed a statistically significant association between a polycystic ovary syndrome (PCOS) and fibrocystic breast disease and women with a PCOS should be evaluated for fibro Cystic Breast disease.

A PROSPECTIVE STUDY TO COMPARE THE EFFICACY OF THREE TREATMENT MODALITIES ON BENIGN BREAST DISEASE VIZ. EVENING PRIMROSE OIL (EPO), DANAZOLAND CENTCHROMAN

TLDR
Centchroman is effective in reducing the sizes of breast lumps, providing relief from mastalgia and in curing cyclical and noncyclical breast pain in the premenopausal women.

Effectiveness of Centchroman on Regression of Fibroadenosis and Mastalgia.

TLDR
This study proves that centchroman is a safe and cost effective drug with significant efficacy on regression of fibroadenosis and mastalgia with minimal side effect.

Mastalgia in Female Medical Students, Mansoura University, Egypt -

TLDR
A larger representative study including non-university and minority populations would be expected to give better epidemiologic and clinical features of mastalgia as well as its effect on women's activity and productivity.

Misir'da Mansoura Üniversitesi Kadin Tip Öğrencilerinde Mastalji

TLDR
A larger representative study including non-university and minority populations would be expected to give better epidemiologic and clinical features of mastalgia as well as its effect on women's activity and productivity.

Alterations in terminal duct diameter and blood flow in the breasts of subjects with polycystic ovary syndrome

TLDR
Gaziosmanpaşa Üniversitesi Tıp Fakültesi, Kadın Hastalıkları ve Doğum Anabilim Dalı, Tokat, Adıyaman.

References

SHOWING 1-10 OF 65 REFERENCES

Fibrocystic "disease" of the breast.

TLDR
Reported surveys showing that oral contraceptives lessen the incidence of fibrocystic disease suggest that hormonal manipulation can effectively reduce the frequency of this disease and possibly in turn the incidenceof mammary cancer.

Inadequate corpus luteal function in women with benign breast diseases.

TLDR
It is indicated that women with benign breast disease have an inadequate corpus luteum function which may be secondary to an ovulation disorder.

Twenty-four-hour preoperative endocrine profiles in women with benign and malignant breast disease.

TLDR
Normal concentrations of a variety of endocrine and other biochemical agents that can stimulate breast tissue growth and/or have been previously reported to be disordered in women with breast cancer are found.

Serum prolactin concentrations in benign breast disease throughout the menstrual cycle.

Steroid dynamics in the normal and carcinomatous mammary gland.

Prolactin response to thyrotropin‐releasing hormone stimulation and dopaminergic inhibition in benign breast disease

TLDR
Two different tests of prolactin storage and control mechanisms, direct stimulation by thyrotropin‐releasing hormone (TRH) and inhibition of dopaminergic control by dom‐peridone, indicate a significant abnormality in patients with severe cyclicalmastalgia and nodular breast disease, but not in those with noncyclical mastalgia.

Release of prolactin, thyrotropin, and growth hormone in women with cyclical mastalgia and fibrocystic disease of the breast

Prolactin (PRL), thyroid stimulating hormone (TSH) and growth hormone (GH) response to metoclopramide and TRH was investigated in seven women with fibrocystic disease and cyclical mastalgia, in eight

A comparison of serum and breast duct fluid‐immunoassayable prolactin and growth hormone with bioassayable lactogenic hormones in healthy women and patients with cystic breast disease

TLDR
It is concluded that lactogenic hormone bioactivity, when assessed by the Nb2 cell assay, is indicative of an endocrine abnormality which is associated with benign breast disease, and is reflected in breast duct fluid, but is not identified by the conventional radioimmunoassays.
...